StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)

Stock analysts at StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a report released on Monday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners began coverage on Lipocine in a report on Tuesday, September 24th. They set a “buy” rating and a $10.00 price target on the stock.

Lipocine Trading Up 4.4 %

Shares of Lipocine stock opened at $5.21 on Monday. The stock has a market cap of $27.86 million, a PE ratio of -6.59 and a beta of 1.24. Lipocine has a 52 week low of $2.44 and a 52 week high of $11.79. The company’s 50-day moving average price is $5.17 and its two-hundred day moving average price is $5.50.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter. On average, equities analysts predict that Lipocine will post -0.78 EPS for the current fiscal year.

Hedge Funds Weigh In On Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP acquired a new stake in shares of Lipocine Inc. (NASDAQ:LPCN) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned 0.22% of Lipocine as of its most recent filing with the Securities & Exchange Commission. 9.11% of the stock is owned by hedge funds and other institutional investors.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.